ABSTRACT
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide, with the highest incidence in Asia and Africa and an increasing incidence in occidental countries (1) . Most HCCs arise in the liver, with underlying diseases induced by persistent hepatitis virus infection, including chronic hepatitis and cirrhosis. In the complex multistage process of hepatocarcinogenesis, the accumulation of genetic and epigenetic alterations involving the inactivation of tumor suppressor genes and the activation of oncogenes is required for the emergence of a fully malignant tumor. The p16 INK4A gene, located on chromosome 9p21, encodes a critical negative regulator of cell cycle progression and is one of the most frequently inactivated tumor suppressor genes detected in various tumor types (2) (3) (4) . The p16
INK4A protein binds to cyclin-dependent kinases 4 and 6 and inhibits the ability of cyclin-dependent kinase 4/6 to phosphorylate the retinoblastoma protein, resulting in G 1 -phase arrest. The p16 INK4A gene was initially thought to be inactivated through endogenous DNA damage events involving homozygous deletions and mutations. However, recent studies have suggested that the p16 INK4A gene can also be silenced epigenetically in human neoplasias through the hypermethylation of the 5Јcytosine phospho guanine island within the promoter region (4) . Accumulating evidence suggests that aberrant promoter methylation is generally correlated with the transcriptional inactivation of defined tumor suppressor genes, which has emerged as a common molecular defect in neoplastic cells. The cause of aberrant DNA methylation in cancer cells remains largely unknown.
We and others shown previously that p16 INK4A is frequently down-regulated in HCC but that mutations or homozygous deletions in this gene are rare (5) (6) (7) . Recently, several studies have identified aberrant promoter methylation as the main mechanism underlying the inactivation of p16
INK4A in HCC (8 -17 
MATERIALS AND METHODS
Patients and Specimens. Tumor and corresponding noncancerous liver tissue specimens were obtained from 50 patients with HCC whose frozen tumor samples had been stored in the surgical pathology files of our department between August 1996 and December 1998. The frozen tissue samples were flashfrozen in liquid nitrogen immediately after surgical resection and stored at Ϫ80°C until analysis. The patients consisted of 38 men and 12 women, ranging in age from 29 to 82 (median, 62.5) years. After Tumor-Node-Metastasis staging (18) , the 50 primary HCCs were divided into 4 stage I lesions, 24 stage II lesions, 19 stage III lesions, and 3 stage IV lesions. Pathologic diagnoses were made based on the classification of the Liver Cancer Study Group of Japan (19) . Of the 50 patients, one exhibited a normal liver, 8 had fibrosis, 12 had chronic hepatitis, and 29 had cirrhosis. Serologic examinations indicated that 13 patients were hepatitis B surface antigen-positive, 32 were antihepatitis C virus antibody (anti-HCV)-positive, and 5 were negative for both hepatitis viral markers. Written informed consent was obtained from each patient, and the protocol of the study was approved by the local ethics committee.
Methylation-Specific PCR Analysis. We extracted genomic DNA from the 50 tumors and the 46 corresponding noncancerous tissues for which frozen samples were available using a DNA isolation kit (GenomicPrep DNA Isolation kit, Amersham Pharmacia Biotech, Piscataway, NJ). After being modified by treatment with sodium bisulfite, we screened the methylation status of the p16 INK4A promoter by PCR using a commercial primer kit (cytosine phospho guanine WIZ p16 Amplification kit, Intergen Company, Purchase, NY): an M primer set, for detecting the methylated DNA sequence; a U primer set, for detecting the unmethylated DNA sequence; and a W primer set, recognizing any unmodified DNA and serving as a control monitoring the efficiency of the bisulfite reaction. Water blanks were used as negative controls. We separated the amplified products electrophoretically on 3% agarose gels and visualized them using ethidium bromide staining.
Reverse Transcription-PCR Analysis. Forty-eight frozen tumors and 36 corresponding noncancerous liver tissue samples from which RNA could be extracted after DNA preparation were used to isolate the total RNA using a RNA isolation method described previously (5). We reverse-transcribed the total RNA using a random hexadeoxynucleotide primer (Takara Shuzo, Otsu, Japan). The following primers, designed to amplify exons 1 and 2 of the p16 INK4A cDNA, were used: sense, 5Ј-CTGCCCAACGCACCGAATAG-3Ј and antisense, 5Ј-TC-AATCGGGGATGTCTGAGG-3Ј (11). ␤-Actin mRNA was simultaneously amplified in each run as a control.
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections from the 50 tumors were used for p16 INK4A immunostaining within 3 days of sectioning. As described in our previous studies (20) , we stained the p16 INK4A protein using a polyclonal anti-p16
INK4A antibody (C-20, dilution, 1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA) according to the avidin-biotin-peroxidase complex method. The tumors were considered to exhibit p16 INK4A protein expression, if the p16 INK4A immunoreactive cells accounted for Ն1% of the total cell population (20) .
Statistical Analysis. The association of p16 INK4A hypermethylation with mRNA and protein expression and clinicopathologic features were evaluated by the 2 test. Survival analysis was done by the Kaplan-Meier method and log-rank test. A P value Ͻ0.05 was considered statistically significant.
RESULTS

p16
INK4A Methylation. Methylation-specific PCR analysis showed aberrant p16 INK4A methylation in 29 (58%) of the 50 HCCs, which generate a methylated PCR product (Fig. 1A) . Of the 46 corresponding noncancerous tissues, a methylation band was not found in the one normal liver tissue specimen or in the seven fibrosis tissue specimens; weak methylation bands were observed in 2 (17%) of the 12 chronic hepatitis tissue specimens and 4 (15%) of the 26 cirrhotic liver tissues specimens. All of the tumor tissues corresponding to these six methylated noncancerous lesions exhibited strong methylation bands. Consistent with previous reports (9, 12, 13), a band of unmethylated products was observed in all samples. No product was observed in negative controls (water blanks). The W primer set did not produce any or only a very slight amount of product, indicating that the bisulfate reactions are efficient. p16 INK4A Expression. Of the 48 tumors examined, p16
INK4A mRNA amplification products were not observed in 31 (65%) tumors; the other 17 (35%) expressed detectable levels of p16
INK4A mRNA (Fig. 1B) . Twenty-seven of the 36 corresponding noncancerous tissues exhibited detectable p16 INK4A mRNA products. To confirm whether a loss of p16
INK4A mRNA expression was actually present, all analyses were repeated at least twice. Close level of the ␤-actin expression was detected in all samples (Fig. 1C) . INK4A genes and undetectable mRNA expression. C, control ␤-actin mRNA is expressed in all cases, including the five cases in which p16
INK4A mRNA expression was not detected. INK4A may be attributable to the low levels of methylation, as illustrated in a previous study on HCC (10) .
Association of p16 INK4A Methylation with Clinicopathologic Features and Survival. p16
INK4A hypermethylation was more frequently observed in HCCs from older patients, and in tumors from women (P ϭ 0.02 and 0.04, 2 test; Table 2 ). p16
INK4A hypermethylation was only detected in hepatitis B virus (HBV) or HCV-related tumors, whereas none of the five virus-negative tumors exhibited aberrant p16
INK4A methylation (P ϭ 0.006, 2 test; Table 2 ). The frequency of p16 INK4A hypermethylation tended to be higher in HCV-related tumors (23 of 32, 72%) than in HBV-related tumors (6 of 13, 46%), although this difference was not statistically significant (P ϭ 0.1, 2 test; Table 2 ). p16 INK4A hypermethylation was more frequently observed in tumors from patients with normal serum levels of protein-induced by vitamin K absence or antagonist II (PIVKA-II; P ϭ 0.04, 2 test; Table 2 ). p16 INK4A methylation was not related to Tumor-Node-Metastasis staging, tumor differentiation, intrahepatic metastasis, portal involvement, hepatic vein involvement, capsular infiltration, tumor size, background liver disease, or serum ␣-fetoprotein levels ( Table 2) . Among the clinicopathologic factors, HCV infection was significantly associated with older patients (P ϭ 0.001, 2 test), compared with HBV infection. Normal PIVKA-II levels were related to advanced age and HBV or HCV infection (P ϭ 0.04 and 0.02, respectively; 2 test). Survival was analyzed in 49 patients, excluding one patient with recurrent HCC. The median follow-up period was 46 (range, 6 -71) months. The 5-year overall survival for the 49 patients was 63%. As shown in Fig. 3 , no difference in diseasefree survival (DFS) was found with regard to p16
INK4A methylation status in the 49 HCCs (P ϭ 0.48, log rank test ; Fig. 3A) ; the 5-year DFS for patients with or without p16
INK4A methylation were 26 and 40%, respectively. When we did the analysis using data for stage I/II tumors only, the 5-year DFS for patients INK4A methylation was 34 and 60%, respectively, but the difference did not reach statistical significance (P ϭ 0.15, log-rank test; Fig. 3B ).
DISCUSSION
Despite remarkable improvements in the diagnosis and treatment of patients with HCC, the long-term prognosis remains generally poor, because of the high incidence of recurrence in the liver remnant. The possible effect of p16 INK4A methylation on the malignant behavior and disease outcome of HCC has not been thoroughly investigated to date. Our results showed that p16
INK4A hypermethylation was present in 58% (29 of 50) of the examined HCCs and 16% (6 of 38) of the precancerous lesions (including chronic hepatitis and cirrhotic tissues) and that p16
INK4A hypermethylation was strongly related to both mRNA and protein expression. In the overall series of HCCs, we failed to find any association between p16 INK4A hypermethylation and clinicopathologic factors related to tumor progression and patient survival. Among patients with stage I/II tumors, however, patients with p16
INK4A methylation had a higher frequency of recurrence than those without p16 INK4A methylation, although the difference was not statistically significant. As only a few stage I/II tumors were included in this study, additional large-scale studies are necessary to obtain conclusive evidence. Taken together, our observations suggest that aberrant p16
INK4A methylation may contribute to hepatocarcinogenesis from early stages even in precancerous lesions and may play a more important role in low-stage tumors than in high-stage tumors during the multistage process of hepatocarcinogenesis. p16
INK4A hypermethylation has also been shown to be an early event in the development of lung and stomach cancers (21, 22) . Positive data about the prognostic significance of p16
INK4A methylation has been limited thus far. Consistent with our preliminary findings, however, one study investigating a relatively large number of lung adenocarcinomas reported that p16
INK4A methylation was an independent risk factor in the prediction of a poor prognosis for patients with stage I tumors but not for patients with other tumor stagings (23) .
Chronic infection with hepatitis B or C virus is a major risk factor for HCC worldwide, although the prevalence of these two viruses varies geographically. In Japan, 60 to 80% of HCC patients are infected with HCV, and 10 to 20% are infected with HBV. In the present study, we showed that p16 INK4A hypermethylation was significantly related to HBV or HCV infection; none of the virus-negative but 46% of the HBV-related and 72% Fig. 3 
